Allergan Joins TriNetX to Access Network of Real-World Data for Clinical Research

Allergan has joined the TriNetX global health research network for real-time access to patient populations, driven and refreshed by clinical data, to determine protocol feasibility, cohort analysis and site identification.

TriNetX’s cloud-based platform, TNX™, provides on-demand access to longitudinal clinical data and a set of highly intuitive analytics capabilities, enabling researchers to design successful protocols, improve site selection and planning, and create real-world evidence (RWE). TriNetX has partnered with leading healthcare organizations, spanning 16 countries, to create the largest global health research network.

To date, TriNetX has been used to analyze over 8,600 protocols; has presented over 2,200 clinical trial opportunities to its healthcare members; and been used for over 75 RWE studies.

“Leveraging ‘Big Data’, especially electronic medical records, in clinical research is a key success factor and a core competency for today’s pharmaceutical companies. Allergan made the strategic decision to invest in this space to further optimize our ability to bring new therapies to market,” said David Nicholson, Chief R&D Officer, for Allergan. “With real-time access to the anonymized real-world data of more than 135 million patients, Allergan will be able to make more informed choices that will enhance and accelerate our clinical trials and development programs.”

Allergan is focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products for patients around the world. Through its Open Science model, a large percentage of Allergan’s pipeline is sourced by partnering with biotech companies, academia and other pharmaceutical companies globally. It has also helped to drive strong R&D productivity by delivering innovative therapies that create long-term shared value for Allergan, for customers and for patients.

“Allergan is an industry leader in its application of technology to support innovation and create efficiencies across research and development,” said Gadi Lachman, president & CEO, of TriNetX.  “With TriNetX, researchers will now be able to optimize the clinical trial design process and conduct observational studies with unparalleled speed and ease.”